NCT01402661
CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry
Enrolling by Invitation
Not specifiedAges 18+ObservationalCorEvitasGovernment-funded
~91,758 participants
Updated 2025-10-02 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patterns, effectiveness, and safety of DMARDs, biologic agents and any other treatments currently used in the management of RA
Measured over Data are collected on subjects for as long as they consent to remain in the study
Conditions
Where it's being run
1 sites across 1 statesMassachusetts1
Study leadership
- Joel Kremer, MD · STUDY_DIRECTOR · Center for Rheumatology
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Exclusion
Eligible Medications are biologics, biosimilars, and JAK-inhibitors FDA-approved for the treatment of RA. Prior use of an Eligible Medication does not exclude a patient from enrollment
What this trial measures
- Patterns, effectiveness, and safety of DMARDs, biologic agents and any other treatments currently used in the management of RAData are collected on subjects for as long as they consent to remain in the study